Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

PanDox: Targeted Doxorubicin in Pancreatic tumours

 PanDox Logo


Feasibility of Enhanced Chemotherapy Delivery to non-resectable Primary Pancreatic Tumours Using Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Focused Ultrasound

Chief Investigator: Prof. Mark Middleton

Sponsor: University of Oxford


Protocol currently awaiting approval.